Flortaucipir F18

氟妥西吡[18F]

Report date: 2026/05/14 20:00:28
NMEFirst In Class

Base Information

Drug NameFlortaucipir F18
Drug Alias Name18F-T807氟[18F]妥西吡18F-flortaucipir氟[18F]滔西吡flortaucipir 18F +[16] 
ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Fluorine > 18F +[5] 
Mechanisms of ActionPositron-emission tomography enhancersMicrotubule-associated protein tau inhibitorsDiagnostic imaging enhancers
TargetsMicrotubule-associated protein tau
Therapy Area/IndicationsDiagnostic agentsCorticobasal degenerationCognitive Dysfunction +[18] 
Global Approved IndicationsDiagnostic agentsAlzheimer Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/05/28
Country/TerritoryCanadaUnited StatesAustralia +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSiemens Medical Solution
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Eli Radiopharma Co LtdPDRadiopharma IncBeijing Xinhe Pharmaceutical Technology Co Ltd +[10] 
Inactive CompaniesThe Brigham and Women's HospitalColumbia UniversityMolecular Neuroimaging Llc
Active IndicationsDiagnostic agentsCognitive DysfunctionCognition Disorders +[8] 
Inactive IndicationsCorticobasal degenerationDepressionTauopathies +[10] 

Other Information

ATC CodeV04C
Related LinksWikipediaDrugBankKEGG